Defining the role of different KRAS effectors in the initiation and progression of lung cancer
Lung cancer is currently the most deadly malignancy in Canada, accounting for 27% of all cancer-related deaths. Over 70% of patients with non-small cell lung cancer (NSCLC) are diagnosed at a late stage, with a 5-year survival below 10%. In NSCLC, the two oncogenes that are most frequently mutated...
| Main Author: | |
|---|---|
| Other Authors: | |
| Format: | Others |
| Language: | en |
| Published: |
McGill University
2013
|
| Subjects: | |
| Online Access: | http://digitool.Library.McGill.CA:80/R/?func=dbin-jump-full&object_id=114259 |